Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06345729
Status:
RECRUITING
Last Update Posted:
2024-07-12
First Post:
2024-03-28
Brief Title:
A Study of MK-1084 Plus Pembrolizumab MK-3475 in Participants With KRAS G12C Mutant Metastatic Non-small Cell Lung Cancer NSCLC With Programmed Cell Death Ligand 1 PD-L1 Tumor Proportion Score TPS 50 MK-1084-004
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-24
Start Date Type:
ACTUAL
Primary Completion Date:
2029-02-19
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-02-18
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-28
First Submit QC Date:
March 28 2024
Study First Post Date:
2024-04-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-17
Last Update Post Date:
2024-07-12
Last Update Post Date Type:
ACTUAL